Ozurdex in age-related macular degeneration as adjunct to ranibizumab (The OARA Study)

Canadian Journal of Ophthalmology

Volumn 51, Issue 4, 2016, Pages 302-305

  Chaudhary, Varun ^a   Barbosa, Joshua ^a   Lam, Wai Ching ^b   Mak, Michael ^b   Mavrikakis, Emmanouil ^c   Mohaghegh P, S Mohammad ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c KAT HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; BRIMONIDINE PLUS TIMOLOL; DEXAMETHASONE; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; DRUG IMPLANT; GLUCOCORTICOID; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CENTRAL MACULAR THICKNESS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC RETINOPATHY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; INTRAVITREAL IMPLANT; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG IMPLANT; INTRAVITREAL DRUG ADMINISTRATION; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; DEXAMETHASONE; DRUG IMPLANTS; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MALE; RANIBIZUMAB; RETINA; SINGLE-BLIND METHOD; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84978512247     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/j.jcjo.2016.04.020     Document Type: Article

References (6)

1. 1 Lotery, A., Trump, D., Progress in defining the molecular biology of age related macular degeneration. Hum Genet 112 (2007), 219–236.
2. 2 Van Lookeren Campagne, M., LeCouter, J., Yaspan, B.L., et al. Mechanisms of age-related macular degeneration and therapeutic opportunities. J Pathol 232 (2014), 151–164.
3. 3 Charbel, I.P., Chong, N.V., Scholl, H.P., The significance of the complement system for the pathogenesis of age-related macular degeneration—current evidence and translation into clinical application. Graefes Arch Clin Exp Ophthalmol 249 (2011), 163–174.
4. 4 Ranchod, T.T.M., Ray, S.K., Daniels, S.A., et al. A prospective study comparing ranibizumab plus dexamethasone combination therapy versus ranibizumab monotherapy for neovascular age-related macular degeneration. Retina 33 (2013), 1600–1604.
5. 5 Holz, F.G., Tadayoni, R., Beatty, S., et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration 99 (2015), 220–226.
6. 6 Finger, R.P., Wickremasinghe, S.S., Baird, P.N., et al. Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration. Survey Ophthalmol 59 (2014), 1–18.